PATENT CLAIM ANALYSIS

Application Number: 16118001
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "356000"]

Abstract:
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.

Claim (Index 2):
The method of  claim 1 , wherein the neurotrophic factor is brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), fibroblast growth factor, basic (bFGF), ciliary neurotrophic factor (CNTF), neurotrophic factors-4/5 (NT-4/5), insulin-like growth factor (IGF), or insulin, or a mimetic thereof.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 96.0
- Lexical Diversity: 1.1875
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15339762', '15812821', '15339752', '14507730', '15988965']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8939673614149406
- 35 USC 102 Novelty (BERT): 0.5876358642516443
- Combined Prediction Score: 0.863334211698611
- Mean Citation Score: 611.4666759999999
- Max Citation Score: 747.0627
- Similarity Product: 410.8826682410002

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test